DRMA - Dermata Therapeutics, Inc.

1.32
-0.020   -1.515%

Share volume: 48,799
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$1.34
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.94%
1 Month
-15.92%
3 Months
-45.23%
6 Months
-67.88%
1 Year
84.98%
2 Year
275.64%
Key data
Stock price
$1.32
P/E Ratio 
N/A
DAY RANGE
$1.28 - $1.39
EPS 
-$4.69
52 WEEK RANGE
$0.57 - $7.14
52 WEEK CHANGE
$66.58
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
4.022 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$102,199
AVERAGE 30 VOLUME 
$269,402
Company detail
CEO: Gerry Proehl
Region: US
Website: dermatarx.com
Employees: 8
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Recent news